Greenwich LifeSciences, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US3968791083

USD

8.80

0.8 (10.0%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Prelude Therapeutics, Inc.

Seer, Inc. (California)

TScan Therapeutics, Inc.

TriSalus Life Sciences, Inc.

Trevi Therapeutics, Inc.

Design Therapeutics, Inc.

Vor Biopharma, Inc.

Greenwich LifeSciences, Inc.

XBiotech, Inc.

INmune Bio, Inc.

BioVie, Inc.

Why is Greenwich LifeSciences, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Greenwich LifeSciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Greenwich LifeSciences, Inc.

-37.54%

-0.83

51.85%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-274.54%

EBIT to Interest (avg)

-10.16

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.10

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.27%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

98.40

EV to EBIT

-7.54

EV to EBITDA

-7.54

EV to Capital Employed

-87.91

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1262.96%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at USD -7.28 MM

DEBT-EQUITY RATIO (HY)

Lowest at -217.1 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-18What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -8.49 MM

PRE-TAX PROFIT(Q)

At USD -4.03 MM has Fallen at -54.42%

NET PROFIT(Q)

At USD -4.03 MM has Fallen at -54.42%

ROCE(HY)

Lowest at -491.94%

Here's what is working for Greenwich LifeSciences, Inc.

Debt-Equity Ratio

Lowest at -217.1 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Greenwich LifeSciences, Inc.

Pre-Tax Profit

At USD -4.03 MM has Fallen at -54.42%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -4.03 MM has Fallen at -54.42%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -8.49 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)